Colorectal cancer, Vitamin D and microbiota: A double-blind Phase II randomized trial (ColoViD) in colorectal cancer patients.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Vitamin D (vitD) blood levels are also inversely correlated with CRC risk and prognosis.

However, these factors' interplay remains unknown.

Who Took Part

The abstract describes 74 patients taking part.

PubMed tags the participants as both men and women.

Baseline and post-treatment fecal microbiota for shotgun metagenomics sequencing was collected.

Coda-lasso and Principal Component Analysis were used to select and summarize treatment-associated taxa and pathways.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

Associations between vitD and taxa/pathways were investigated with logistic regression.

Mediation analysis was performed to study if treatment-associated taxa mediated the effect of supplementation on 25(OH)D levels.

What Was Measured

Vitamin D (vitD) blood levels are also inversely correlated with CRC risk and prognosis.

Topics PubMed links to this paper include Vitamin D, Vitamins, Dietary Supplements, Colorectal Neoplasms and Microbiota.

Author keywords: Colorectal cancer, Gender, Microbiome and Sex.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 74 patients.

Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Neoplasia (New York, N.Y.)), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.